Zoetis (ZTS) Asset Writedowns and Impairment (2012 - 2026)
Zoetis (ZTS) posted quarterly Asset Writedowns and Impairment of $13.0 million for Q1 2026, up 550.0% year-over-year from $2.0 million in Q1 2025, and down 55.17% quarter-over-quarter from $29.0 million in Q4 2025.
Zoetis (ZTS) Asset Writedowns and Impairment (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Asset Writedowns and Impairment for 15 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 550.0% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $64.0 million (up 128.57% YoY), while the FY2025 annual figure was $68.0 million, down 29.9% from the prior year.
- Asset Writedowns and Impairment declined to $13.0 million in Q1 2026 per ZTS's latest filing, from $29.0 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $88.0 million in Q4 2023 and bottomed at $1.0 million in Q1 2022.
- Historically, Asset Writedowns and Impairment has averaged $19.4 million across 5 years, with a median of $16.0 million in 2023.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment surged 2100.0% — and 2025, when it slumped 88.24%.
- Zoetis' Asset Writedowns and Impairment stood at $4.0 million in 2022, then soared by 2100.0% to $88.0 million in 2023, then sank by 70.45% to $26.0 million in 2024, then advanced by 11.54% to $29.0 million in 2025, then sank by 55.17% to $13.0 million in 2026.
- Business Quant data shows ZTS's Asset Writedowns and Impairment at $13.0 million in Q1 2026, $29.0 million in Q4 2025, and $22.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.00 Mn |
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 29.00 Mn |
| Dec 31, 2025 | 29.00 Mn |
| Jun 30, 2025 | 22.00 Mn |
| Jun 30, 2025 | 22.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Mar 31, 2024 | 17.00 Mn |
| Mar 31, 2024 | 17.00 Mn |
| Dec 31, 2023 | 88.00 Mn |
| Dec 31, 2023 | 88.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 31.00 Mn |
| Jun 30, 2023 | 31.00 Mn |
| Mar 31, 2023 | 16.00 Mn |
| Mar 31, 2023 | 16.00 Mn |